文献速递冠心病血脂与心血管预防

费用分担政策变化对急性冠脉综合征患者循证用药依从性的影响

Effect of cost sharing on adherence to evidence-based medications in patients with acute coronary syndrome.
PubMed 文献 · Heart · 2017-03-01

西班牙巴伦西亚自治区2012年7月调整药品费用分担方案后,基于2009—2011年10 563例急性冠脉综合征存活出院患者的回顾性人群队列发现,低价、患者自付上限低的抗血小板药和β受体阻滞剂依从性无显著变化;较贵的ACEI/ARB和他汀在养老金领取组依从性分别下降6.8%和8.3%(均P<0.01),中高收入工作组他汀不依从性增加7.8%(P<0.01),效应似为暂时性。作者认为费用分担变化可能导致循证有效治疗依从性下降,应考虑对高危患者全额豁免药品费用分担。

要点

  • 抗血小板药和β受体阻滞剂等低价、低自付上限药物,干预组与对照组依从性无显著差异。
  • 养老金领取组较对照组ACEI/ARB依从性下降6.8%、他汀下降8.3%,均P<0.01。
  • 中高收入工作组较对照组他汀不依从性增加7.8%(P<0.01),效应似为暂时性。

核心结论

  • 费用分担变化可能导致循证有效治疗依从性下降,尤其是价格较高、患者自付比例较高的药物。
  • 作者认为应考虑对高危患者全额豁免药品费用分担。

研究设计与样本

  • 基于人群的回顾性队列研究,纳入2009—2011年急性冠脉综合征存活出院患者10 563例。
  • 设对照组(低收入工作人群,共保状态未变)和两个干预组:养老金领取组由全额报销变为10%共保;中高收入工作组共保比例由40%升至50%或60%。
  • 从首次处方日期起测量每周依从率,通过链接随访期内处方与配药记录估算有药可用天数。

主要发现

  • 对于低价且患者自付上限低的抗血小板药和β受体阻滞剂,干预组与对照组依从性无显著差异。
  • 对于较贵的ACEI/ARB和他汀,养老金领取组较对照组依从性立即下降,分别下降6.8%和8.3%(均P<0.01)。
  • 对于他汀,中高收入工作组较对照组不依从性增加7.8%(P<0.01)。
  • 上述效应似为暂时性。

关键数值与推荐

  • 养老金领取组较对照组ACEI/ARB依从性下降6.8%(P<0.01)。
  • 养老金领取组较对照组他汀依从性下降8.3%(P<0.01)。
  • 中高收入工作组较对照组他汀不依从性增加7.8%(P<0.01)。

临床怎么用

  • 作者认为应考虑对高危患者全额豁免药品费用分担。
  • 原文未据此给出其他临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Cost-sharing scheme for pharmaceuticals in Spain changed in July 2012. Our aim was to assess the impact of this change on adherence to essential medication in patients with acute coronary syndrome (ACS) in the region of Valencia. METHODS: Population-based retrospective cohort of 10 563 patients discharged alive after an ACS in 2009-2011. We examined a control group (low-income working population) that did not change their coinsurance status, and two intervention groups: pensioners who moved from full coverage to 10% coinsurance and middle-income to high-income working population, for whom coinsurance rose from 40% to 50% or 60%. Weekly adherence rates measured from the date of the first prescription. Days with available medication were estimated by linking prescribed and filled medications during the follow-up period. RESULTS: Cost-sharing change made no significant differences in adherence between intervention and control groups for essential medications with low price and low patient maximum coinsurance, such as antiplatelet and beta-blockers. For costlier ACE inhibitor or an angiotensin II receptor blocker (ACEI/ARB) and statins, it had an immediate effect in the proportion of adherence in the pensioner group as compared with the control group (6.8% and 8.3% decrease of adherence, respectively, p<0.01 for both). Adherence to statins decreased for the middle-income to high-income group as compared with the control group (7.8% increase of non-adherence, p<0.01). These effects seemed temporary. CONCLUSIONS: Coinsurance changes may lead to decreased adherence to proven, effective therapies, especially for higher priced agents with higher patient cost share. Consideration should be given to fully exempt high-risk patients from drug cost sharing.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. González López-Valcárcel B, Librero J, García-Sempere A, et al. Effect of cost sharing on adherence to evidence-based medications in patients with acute coronary syndrome. Heart. 2017. PMID: 28249992. doi:10.1136/heartjnl-2016-310610

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。